TrialThe Lancet. Respiratory medicine2021

Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial.

Liam G Heaney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.